![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: RTN4RL2 |
Gene summary for RTN4RL2 |
![]() |
Gene information | Species | Human | Gene symbol | RTN4RL2 | Gene ID | 349667 |
Gene name | reticulon 4 receptor like 2 | |
Gene Alias | NGRH1 | |
Cytomap | 11q12.1 | |
Gene Type | protein-coding | GO ID | GO:0006950 | UniProtAcc | Q86UN3 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
349667 | RTN4RL2 | HCC1_Meng | Human | Liver | HCC | 8.77e-39 | 1.08e-01 | 0.0246 |
349667 | RTN4RL2 | HCC1 | Human | Liver | HCC | 3.04e-04 | 1.45e+00 | 0.5336 |
349667 | RTN4RL2 | HCC2 | Human | Liver | HCC | 1.03e-17 | 2.90e+00 | 0.5341 |
349667 | RTN4RL2 | S014 | Human | Liver | HCC | 1.04e-02 | 2.32e-01 | 0.2254 |
349667 | RTN4RL2 | S015 | Human | Liver | HCC | 8.79e-07 | 3.94e-01 | 0.2375 |
349667 | RTN4RL2 | S016 | Human | Liver | HCC | 5.68e-08 | 3.23e-01 | 0.2243 |
349667 | RTN4RL2 | S028 | Human | Liver | HCC | 1.46e-02 | 2.25e-01 | 0.2503 |
349667 | RTN4RL2 | S029 | Human | Liver | HCC | 2.86e-04 | 2.31e-01 | 0.2581 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00310992 | Liver | HCC | regeneration | 107/7958 | 198/18723 | 6.67e-04 | 4.12e-03 | 107 |
GO:001097511 | Liver | HCC | regulation of neuron projection development | 220/7958 | 445/18723 | 1.68e-03 | 8.78e-03 | 220 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RTN4RL2 | SNV | Missense_Mutation | novel | c.512N>T | p.Gln171Leu | p.Q171L | Q86UN3 | protein_coding | tolerated(0.07) | benign(0.187) | TCGA-AP-A1DO-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
RTN4RL2 | SNV | Missense_Mutation | novel | c.199N>A | p.Leu67Met | p.L67M | Q86UN3 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AP-A1E3-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
RTN4RL2 | SNV | Missense_Mutation | novel | c.32C>T | p.Ala11Val | p.A11V | Q86UN3 | protein_coding | tolerated_low_confidence(0.3) | benign(0) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
RTN4RL2 | SNV | Missense_Mutation | novel | c.1240N>A | p.Leu414Ile | p.L414I | Q86UN3 | protein_coding | tolerated_low_confidence(0.29) | benign(0) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
RTN4RL2 | SNV | Missense_Mutation | rs755532417 | c.226N>T | p.Arg76Trp | p.R76W | Q86UN3 | protein_coding | deleterious(0.01) | probably_damaging(0.986) | TCGA-BG-A0VX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
RTN4RL2 | SNV | Missense_Mutation | c.158N>T | p.Ser53Phe | p.S53F | Q86UN3 | protein_coding | deleterious(0) | benign(0.136) | TCGA-BS-A0UV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
RTN4RL2 | SNV | Missense_Mutation | novel | c.136T>C | p.Cys46Arg | p.C46R | Q86UN3 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-D1-A175-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
RTN4RL2 | SNV | Missense_Mutation | novel | c.712N>C | p.Ser238Arg | p.S238R | Q86UN3 | protein_coding | deleterious(0) | possibly_damaging(0.763) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
RTN4RL2 | SNV | Missense_Mutation | novel | c.259C>A | p.Leu87Met | p.L87M | Q86UN3 | protein_coding | deleterious(0) | probably_damaging(0.983) | TCGA-SJ-A6ZI-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
RTN4RL2 | SNV | Missense_Mutation | rs140089941 | c.37G>A | p.Ala13Thr | p.A13T | Q86UN3 | protein_coding | tolerated_low_confidence(0.08) | benign(0.223) | TCGA-55-6987-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |